Free Trial
NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

$0.38
0.00 (0.00%)
(As of 09/6/2024 ET)
Today's Range
$0.38
$0.38
50-Day Range
$0.38
$0.38
52-Week Range
$0.36
$4.80
Volume
N/A
Average Volume
191,869 shs
Market Capitalization
$1.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NBSE stock logo

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Stock Price History

NBSE Stock News Headlines

‘Wheels Are Falling Off’ the U.S. Stock Market
"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."
‘Wheels Are Falling Off’ the U.S. Stock Market
"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. (NBSE)
NeuBase Therapeutics Inc (O7P.BE)
CMU halts licensing agreement with NeuBase Therapeutics
NeuBase Therapeutics Inc NBSE
NeuBase Therapeutics, Inc. (NBSE.MX)
Massive Insider Trade At NeuBase Therapeutics
See More Headlines
Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/23/2021
Today
9/09/2024
Next Earnings (Estimated)
9/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBSE
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.04 per share

Miscellaneous

Free Float
3,456,000
Market Cap
$1.42 million
Optionable
Not Optionable
Beta
0.95
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

NBSE Stock Analysis - Frequently Asked Questions

How have NBSE shares performed this year?

NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of the year. Since then, NBSE shares have decreased by 48.7% and is now trading at $0.38.
View the best growth stocks for 2024 here
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) posted its quarterly earnings results on Thursday, December, 23rd. The company reported ($4.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40.

When did NeuBase Therapeutics' stock split?

NeuBase Therapeutics shares reverse split on the morning of Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN) and Pfizer (PFE).

This page (NASDAQ:NBSE) was last updated on 9/9/2024 by MarketBeat.com Staff

From Our Partners